Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISIONARY-MS LTE: Long-Term Extension of CNM-Au8 in Stable Relapsing MS
NCT04626921Phase 3Completed
- Sponsor
- Clene Inc.
- Start
- Oct 2020
- Primary completion
- May 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of CNM-Au8 in multiple sclerosis (MS), sponsored by Clene Inc. Primary endpoints: Change in Best-Corrected Low-Contrast Letter Acuity score at 2 years and Incidence of treatment-emergent Adverse Events at 2 years. Started Oct 2020; status: completed.
02
Drugs
CNM-Au8
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04626921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626921.